SERA vs. AIRS, VMD, TOI, DCGO, XGN, EUDA, QIPT, NAKA, KDLY, and ATPC
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include AirSculpt Technologies (AIRS), Viemed Healthcare (VMD), Oncology Institute (TOI), DocGo (DCGO), Exagen (XGN), EUDA Health (EUDA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry.
Sera Prognostics vs. Its Competitors
Sera Prognostics (NASDAQ:SERA) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.
AirSculpt Technologies has higher revenue and earnings than Sera Prognostics. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sera Prognostics and Sera Prognostics both had 1 articles in the media. AirSculpt Technologies' average media sentiment score of 1.02 beat Sera Prognostics' score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the news media.
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Comparatively, 76.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Sera Prognostics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.
AirSculpt Technologies has a consensus target price of $3.75, indicating a potential downside of 30.17%. Given AirSculpt Technologies' stronger consensus rating and higher possible upside, analysts plainly believe AirSculpt Technologies is more favorable than Sera Prognostics.
AirSculpt Technologies has a net margin of -9.95% compared to Sera Prognostics' net margin of -28,685.22%. AirSculpt Technologies' return on equity of -15.01% beat Sera Prognostics' return on equity.
Summary
AirSculpt Technologies beats Sera Prognostics on 12 of the 14 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
This page (NASDAQ:SERA) was last updated on 7/8/2025 by MarketBeat.com Staff
